Sitek J C, Loeb M, Ronnevig J R
Department of Dermatology, Ulleval University Hospital, Oslo, Norway.
J Eur Acad Dermatol Venereol. 2007 Aug;21(7):891-6. doi: 10.1111/j.1468-3083.2007.01980.x.
Since 1997, a number of trials have shown promising results in treating generalized vitiligo with narrowband ultraviolet B (UVB) both in adults and children. However, there is little knowledge concerning the duration and permanency of the treatment-induced repigmentation.
Our main objective was to perform a follow-up trial of successfully treated patients receiving narrowband UVB for generalized vitiligo.
We have investigated to what degree the treatment-induced repigmentation remains stable for up to 2 years post-treatment. We performed an initial open trial including 31 patients with generalized vitiligo. They received narrowband UVB thrice weekly for up to 12 months. Patients experiencing > 75% repigmentation were defined responders and were included in the follow-up trial. Responders were followed every 6 months for up to 2 years after cessation of treatment. We observed the pigmentation status and registered any changes indicating loss of pigmentation and relapse.
Eleven of the 31 treated patients were included in the follow-up trial. Six patients had relapse and five patients had stable response 24 months after cessation of treatment. Four out of six relapses were within 6 months post-treatment.
In our study population of 31 patients with generalized vitiligo, five patients (16%) experienced > 75% stable repigmentation 2 years after cessation of a treatment programme of up to 1 years narrowband UVB therapy.
自1997年以来，多项试验表明，窄谱中波紫外线（UVB）治疗成人和儿童泛发性白癜风取得了令人鼓舞的结果。然而，对于治疗引起的色素再生的持续时间和持久性知之甚少。
我们的主要目的是对接受窄谱UVB治疗泛发性白癜风的成功治疗患者进行随访试验。
我们研究了治疗引起的色素再生在治疗后长达2年的时间内保持稳定的程度。我们进行了一项初始开放性试验，纳入31例泛发性白癜风患者。他们每周接受3次窄谱UVB治疗，持续12个月。色素再生超过75%的患者被定义为反应者，并纳入随访试验。反应者在治疗停止后每6个月随访一次，持续2年。我们观察色素沉着状态，并记录任何表明色素脱失和复发的变化。
31例接受治疗的患者中有11例纳入随访试验。6例患者复发，5例患者在治疗停止24个月后反应稳定。6例复发患者中有4例在治疗后6个月内复发。
在我们的31例泛发性白癜风患者研究人群中，5例患者（16%）在长达1年的窄谱UVB治疗方案停止2年后色素再生稳定超过75%。
